⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GLUE News
Monte Rosa Therapeutics, Inc. Common Stock
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases
globenewswire.com
GLUE
Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates
globenewswire.com
GLUE
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com
GLUE
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases
globenewswire.com
GLUE